CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 1a265041-dcba-4d47-9a2a-af0e73104267
exploratory
The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.
Contradiction: none
Sources: 5
exploratoryInterpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Contradiction: none
Sources: 5
exploratoryReal tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.
Contradiction: none
Sources: 5
exploratory_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._
Contradiction: none
Sources: 5
exploratory`fact_id=90736` (`B_context`) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581
Contradiction: none
Sources: 5
exploratory`fact_id=164159` (`A_core`) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Contradiction: none
Sources: 5